Latest News and Press Releases
Want to stay updated on the latest news?
-
– License of proprietary RFdiffusion-based model, RFpeptides, provides Vilya with another powerful structure prediction framework for rapid and unique design of potent and selective macrocycles for...
-
Founder and lead investor ARCH Venture Partners is joined by NVIDIA’s NVentures, Menlo Ventures, and MadronaFunding accelerates advancement of Vilya's proprietary computational drug design and...
-
– Company creating de novo designed macrocycles with enhanced efficacy that precisely target disease biology – Vilya’s privileged macrocycles have the potential to be applied across broad...